PURPOSE: To evaluate clinical outcomes, visual acuity, and the range of vision in patients implanted with the enVista Aspire “monofocal plus” intraocular lens (IOL), designed to provide an extended range of vision through a proprietary aspheric surface.

SETTING: Single-Center in Poland

METHODS: This prospective clinical study included 64 eyes of 32 patients who underwent bilateral cataract surgery with implantation of the enVista Aspire IOL. Standard phacoemulsification was performed in all cases. Outcome measures assessed at 3 months postoperatively included uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA) at 66 cm, and manifest refractive spherical equivalent (MRSE). Patient satisfaction and the presence of photic phenomena (glare and halos) were evaluated using a standardized questionnaire.

RESULTS: Postoperative refractive outcomes demonstrated high predictability, with a mean MRSE of −0.28 ± 0.46 D. Visual performance was excellent at both distance and intermediate ranges. Mean binocular postoperative UDVA was 0.03 ± 0.03 logMAR (20/20 Snellen equivalent), while mean binocular postoperative UIVA at 66 cm was 0.22 ± 0.10 logMAR (approximately 20/32 Snellen equivalent), indicating a smooth transition between distance and intermediate vision. The mean postoperative sphere was −0.24 ± 0.45 D, and the mean prediction error (PRA) was 0.46 ± 0.53 D. No significant intraoperative or postoperative complications were observed, and no clinically relevant photic phenomena were reported during the follow-up period.

CONCLUSIONS: The enVista Aspire IOL delivers excellent visual outcomes, achieving full restoration of distance vision and functional intermediate visual acuity. The lens demonstrates high refractive predictability and provides an extended range of vision suitable for modern intermediate visual demands, without the visual disturbances commonly associated with multifocal IOLs. It represents an effective and reliable “monofocal plus” option for cataract surgery.